Market
What product types will Novo Nordisk's Odense facility produce by end of 2029?
2
Resolution / Starting Odds
Only haemophilia products • 25%
Haemophilia and one other product type • 25%
Haemophilia and multiple other product types • 25%
No production • 25%
Official announcements from Novo Nordisk or credible news reports
Story
Novo Nordisk Invests $1.2 Billion in Odense Facility for Rare Diseases
Dec 16, 2024, 07:35 AM
Novo Nordisk A/S, the Danish pharmaceutical giant known for its diabetes and weight-loss treatments like Ozempic and Wegovy, has announced a significant investment of $1.2 billion (8.5 billion Danish kroner) to establish a new production facility in Odense, Denmark. This marks the first time in this century that Novo Nordisk is building a new production site in Denmark. The facility, which will span over 40,000 square meters, is designed to be modular and flexible, accommodating multiple product types for rare diseases such as haemophilia. The investment aims to meet the growing global demand for Novo Nordisk's life-changing medicines. Construction is set to begin immediately, with completion expected by 2027, and the facility is projected to create 400 permanent jobs upon completion. This move comes shortly after Novo Nordisk received approval for its $11.7 billion acquisition of three Catalent facilities in the US, Italy, and Belgium, further expanding its production capabilities.
View original story
Similar markets
Seek further trials • 25%
Discontinue development • 25%
Submit for regulatory approval • 25%
Partner with another company • 25%
Safety label update • 25%
No action taken • 25%
Product recall • 25%
Other regulatory actions • 25%
Pursue mergers or acquisitions • 25%
Develop a new obesity drug • 25%
Focus on improving CagriSema • 25%
Increase investment in marketing existing drugs • 25%
Decrease • 25%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%